MRI-Guided Radiotherapy Treatment Modalities and Tumor Site Applications

Why Treatment Modality Sets the Delivery Requirement

A radiation oncology department does not buy a platform in the abstract. It buys the ability to run particular treatment programs, and the modality of those programs sets what the platform must be able to do at the point of delivery.

Within the global MRI-guided radiation therapy systems market, modality is therefore the first lens for understanding why a given center specifies an MRI-guided system, and treatment site is a second lens that explains interest in particular tumor categories.

This page describes the five treatment modalities and eight tumor site categories tracked in this report. They are treated as application categories for market segmentation only, and this report makes no statement about clinical outcomes, effectiveness or patient selection for any modality or site.

The distinction between the two lenses is worth keeping. Modality describes how treatment is delivered: in how many sessions, at what precision and with what adaptation. Treatment site describes where in the body a program is aimed, and interest in a site tends to arise from the programs a center has built around it.

A center with a large stereotactic program and a center with a large prostate program may therefore specify different platforms for different reasons, even though both are buying an MRI-guided system. Reading modality and site separately keeps those two reasons from being confused.

For market analysis the modality dimension is the more stable of the two, because the delivery requirements of a modality persist across sites, while site interest shifts as programs are opened or consolidated.

External Beam Radiation Therapy and Hypofractionated Radiotherapy

External beam radiation therapy is the broadest modality category in this report. It covers treatment in which radiation is delivered from outside the body by a linear accelerator or comparable unit, and it is the context in which most MRI-guided platforms are specified.

Hypofractionated radiotherapy is tracked as a separate category because it changes the demand profile of a platform. It refers to delivering a course of treatment in fewer, larger sessions than a conventional schedule, which concentrates the use of each session and raises the importance of imaging and positioning at the point of delivery.

For a buyer, the practical consequence is throughput planning. A department running hypofractionated schedules thinks differently about room time, staffing per session and the number of platforms it needs than one running longer conventional courses.

External beam is also the modality that links the MRI-guided category to the wider radiotherapy equipment base. Many centers already run external beam programs on conventional linear accelerators, and the question for them is which programs justify adding an MRI-guided platform alongside the existing fleet.

Suppliers address this by offering MRI-guided platforms that can run the same external beam programs as a conventional unit in addition to adaptive work, so the platform can be specified for a mixed workload rather than for adaptive treatment alone.

This report records external beam radiation therapy as the largest treatment modality category by value, a reflection of how much of the radiotherapy base it represents, without any comparison of how one modality performs against another.

Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery

Stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) are the two stereotactic modality categories. Both refer to delivery to a precisely defined target in a small number of sessions, with SBRT applied to targets outside the brain and SRS to intracranial targets.

Stereotactic programs map onto MRI-guided stereotactic radiotherapy systems, the system type category built around positioning, imaging at the time of treatment and motion management integration, though other system types can also be specified for them.

The stereotactic modalities set a distinctive delivery requirement. Because a small number of sessions carry the full course, buyers place weight on how a platform images the target, positions the patient and manages movement during delivery, and these are the capability categories this report tracks.

Stereotactic programs are concentrated at academic medical centers, comprehensive cancer centers, university hospitals and specialty radiation oncology clinics, which have the physics and physician resources such programs require.

The two modalities differ in their equipment context. SRS has a long-standing set of dedicated platforms outside this report's scope, while SBRT is more commonly run on general-purpose linear accelerators, so the MRI-guided category competes for stereotactic programs with a broader set of alternatives than it does for adaptive work.

Demand in this category therefore depends on how many centers choose to place their stereotactic work on an MRI-guided platform, which in turn depends on the centers' own mix of programs, space and budget.

Adaptive Fractionated Therapy

Adaptive fractionated therapy is the fifth modality category and the one most closely tied to the MRI-guided category. It refers to treatment in which the plan is revisited and, where the program calls for it, modified between or during sessions using the imaging acquired on the day.

It is tracked as a modality rather than only as a software feature because it changes how the whole session is organized. An adaptive session adds imaging review, contouring, replanning and plan checking steps, and these steps involve physics, physician and technologist time that a non-adaptive session does not.

For that reason adaptive fractionated therapy is the fastest-growing modality category in this report, a statement about the expansion of adaptive programs and the platforms specified for them, not about the comparative performance of adaptive treatment.

The category depends on the software layer as much as the hardware. Automated contouring, AI-assisted planning and motion management integration all reduce the effort of an adaptive session, and the readiness of that software is a major factor in whether a center opens an adaptive program.

Adaptive fractionated therapy also changes service needs. Centers running adaptive programs rely more heavily on training and certification services, clinical workflow consulting and remote diagnostics, so the modality pulls service categories into the purchase alongside the platform.

Because adaptive programs are newer than conventional ones at many centers, they are also where buyers most often ask a supplier about its upgrade roadmap, since the software available at installation will not be the software in use years later.

Thoracic, Abdominal and Pelvic Treatment Site Categories

The application dimension in this report lists eight treatment site categories. Three groups of them, thoracic, abdominal and pelvic, share a common feature that explains interest in MRI-guided platforms: the targets sit among organs that move.

Lung cancer treatment is the thoracic category in this report. Pancreatic and liver cancer treatment are the abdominal categories, and prostate cancer treatment is the pelvic category tracked as its own application.

Because those organs shift with breathing, digestion and filling, interest in these sites is closely tied to online adaptive radiotherapy and to real-time tumor tracking, the workflow capabilities that let a center account for that movement.

These categories are recorded as application categories only. This report does not state how well any platform treats any site, and it does not recommend any site as a program for a center to open.

Commercially, the thoracic, abdominal and pelvic groups matter because they are large program areas at most comprehensive cancer centers. A center that already treats a high volume at a site has an established case for evaluating any platform positioned around that site.

The sites also differ in program structure. Some sit within a stereotactic program, others within a longer conventional or hypofractionated schedule, which is why the same site can appear in different platform specifications depending on the center's treatment philosophy.

Brain, Head and Neck, Gynecologic and Pediatric Treatment Site Categories

Brain tumor treatment, head and neck oncology, gynecologic oncology and pediatric oncology complete the application dimension. They are grouped here because each is a specialized program area that tends to be run by a smaller set of centers than the larger thoracic, abdominal and pelvic programs.

Brain tumor treatment is the application category most closely connected to stereotactic radiosurgery, and head and neck oncology is a category where treatment planning complexity and imaging at the point of delivery both feature in platform discussions.

Gynecologic oncology is tracked as its own category because the programs that treat it are organized separately at many centers, even though the targets lie in the pelvis. Pediatric oncology is a specialized program area concentrated in children's hospitals and the pediatric units of academic centers.

Specialized programs shape the market in a particular way. Because they are run by fewer centers, they influence platform specification at those centers disproportionately, and they often serve as reference programs that a supplier uses to demonstrate a platform to other buyers.

Reference sites matter in this category because purchases are long-cycle capital decisions. A supplier with a visible installation in a specialized program has a concrete example to show prospective buyers, and clinical trial participation requirements can also direct a center toward a particular platform.

As with the other sites, these categories are recorded for segmentation only, and the full report holds the detailed application breakdown.